{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:09:09Z","timestamp":1789366149589,"version":"build-2803163510"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,7,2]]},"DOI":"10.1097\/01.aids.0000131334.38172.01","type":"journal-article","created":{"date-parts":[[2004,8,31]],"date-time":"2004-08-31T15:23:10Z","timestamp":1093965790000},"page":"1443-1451","source":"Crossref","is-referenced-by-count":127,"title":["Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe"],"prefix":"10.1097","volume":"18","member":"276","reference":[{"key":"R1-11-20210130","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study.","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"R2-11-20210130","first-page":"383","article-title":"Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.","volume":"25","author":"Vigouroux","year":"1999","journal-title":"Diabet Metab"},{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/00002030-199912240-00002","article-title":"Fat distribution and metabolic changes in patients with HIV infection.","volume":"13","author":"Safrin","year":"1999","journal-title":"AIDS"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/135965350100600102","article-title":"Antiretroviral therapy and the lipodystrophy syndrome.","volume":"6","author":"John","year":"2001","journal-title":"Antivir Ther"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1210\/jc.2002-020794","article-title":"Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients.","volume":"87","author":"Chen","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jc.2002-021704","article-title":"Clinical review 159. Human immunodeficiency virus\/highly active antiretroviral therapy- associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies.","volume":"88","author":"Leow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-11-20210130","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.","volume":"361","author":"Carr","year":"2003","journal-title":"Lancet"},{"key":"R8-11-20210130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00126334-200308150-00004","article-title":"An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score.","volume":"33","author":"Carr","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-11-20210130","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/00002030-200112070-00009","article-title":"Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.","volume":"15","author":"Brambilla","year":"2001","journal-title":"AIDS"},{"key":"R10-11-20210130","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/00002030-200009290-00008","article-title":"Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.","volume":"14","author":"Jaquet","year":"2000","journal-title":"AIDS"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00126334-200105010-00005","article-title":"Lipodystrophy in HIV-infected children is associated with high viral load and low CD4 lymphocyte count and CD4 lymphocyte percentage at baseline and use of protease inhibitors and stavudine.","volume":"27","author":"Arpadi","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-11-20210130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.inf.0000068209.03069.2e","article-title":"Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors.","volume":"22","author":"Bockhorst","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00006454-200205000-00011","article-title":"Lipodystrophy syndrome in human immunodeficiency virus-infected children.","volume":"21","author":"Amaya","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/00126334-200304150-00003","article-title":"Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.","volume":"32","author":"Vigano","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-11-20210130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00126334-200207010-00004","article-title":"Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases.","volume":"30","author":"Cheseaux","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-11-20210130","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00002030-200306130-00006","article-title":"Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.","volume":"17","author":"Bitnun","year":"2003","journal-title":"AIDS"},{"key":"R17-11-20210130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/00002030-200104130-00012","article-title":"HIV-infected pregnant women and vertical transmission in Europe since 1986.","volume":"15","year":"2001","journal-title":"AIDS"},{"key":"R18-11-20210130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00126334-200308150-00013","article-title":"Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women?","volume":"33","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-11-20210130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00002030-199802000-00011","article-title":"Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis.","volume":"12","author":"Kind","year":"1998","journal-title":"AIDS"},{"key":"R20-11-20210130","doi-asserted-by":"crossref","first-page":"F241","DOI":"10.1097\/00002030-199818000-00002","article-title":"Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects.","volume":"12","author":"Lorenzi","year":"1998","journal-title":"AIDS"},{"key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jama.284.2.190","article-title":"Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection.","volume":"284","author":"de Martino","year":"2000","journal-title":"JAMA"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1542\/peds.90.3.369","article-title":"Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission.","volume":"90","author":"Gabiano","year":"1992","journal-title":"Pediatr"},{"key":"R23-11-20210130","first-page":"1","article-title":"1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age.","volume":"43","year":"1994","journal-title":"MMWR"},{"key":"R24-11-20210130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study.","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"R26-11-20210130","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","article-title":"Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.","volume":"16","author":"Joly","year":"2002","journal-title":"AIDS"},{"key":"R27-11-20210130","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"R28-11-20210130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00042560-200208010-00010","article-title":"Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.","volume":"30","author":"Heath","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-11-20210130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002030-200101260-00013","article-title":"Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database.","volume":"15","author":"Heath","year":"2001","journal-title":"AIDS"},{"key":"R30-11-20210130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.","volume":"32","author":"Lichtenstein","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-11-20210130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1464-2662.2001.00100.x","article-title":"Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment.","volume":"3","author":"Mauss","year":"2002","journal-title":"HIV Med"},{"key":"R33-11-20210130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00126334-200209010-00007","article-title":"Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study.","volume":"31","author":"Bernasconi","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-11-20210130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00126334-200309010-00008","article-title":"Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns.","volume":"34","author":"Galli","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-11-20210130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature.","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"R36-11-20210130","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1542\/peds.110.5.e56","article-title":"Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.","volume":"110","author":"Lainka","year":"2002","journal-title":"Pediatrics"},{"key":"R37-11-20210130","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. the Swiss HIV Cohort Study.","volume":"100","author":"Periard","year":"1999","journal-title":"Circulation"},{"key":"R38-11-20210130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00002030-200104130-00008","article-title":"Sex differences in HAART-associated dyslipidaemia.","volume":"15","author":"Pernerstorfer-Schoen","year":"2001","journal-title":"AIDS"},{"key":"R39-11-20210130","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"R40-11-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1468-1293.2003.00138.x","article-title":"Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.","volume":"4","author":"Law","year":"2003","journal-title":"HIV Med"},{"key":"R41-11-20210130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1651-2227.2003.tb00535.x","article-title":"Management of vertically HIV-infected children in Europe.","volume":"92","year":"2003","journal-title":"Acta Paediatr"},{"key":"R42-11-20210130","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1542\/peds.111.3.e275","article-title":"Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.","volume":"111","author":"McComsey","year":"2003","journal-title":"Pediatrics"},{"key":"R44-11-20210130","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy.","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"R46-11-20210130","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2165\/00003495-200060060-00012","article-title":"Amprenavir: a review of its clinical potential in patients with HIV infection.","volume":"60","author":"Noble","year":"2000","journal-title":"Drugs"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200407020-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:23:30Z","timestamp":1785785010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200407020-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,2]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aids.0000131334.38172.01","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7,2]]}}}